Stay updated on Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.

Latest updates to the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.6%
- Check10 days agoChange DetectedThe page has removed a citation regarding the genetic basis for clinical response to CTLA-4 blockade in melanoma, including an erratum reference.SummaryDifference0.2%
- Check18 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check39 days agoChange DetectedThe page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, and the revision number has changed from v2.16.0 to v2.16.1.SummaryDifference1.0%
Stay in the know with updates to Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.